D. Boral Capital Maintains Buy on AVITA Medical, Maintains $14 Price Target
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
D. Boral Capital analyst Jason Kolbert maintains AVITA Medical (NASDAQ:RCEL) with a Buy and maintains $14 price target.
D. Boral Capital analyst Jason Kolbert maintains AVITA Medical (NASDAQ:RCEL) with a Buy and maintains $14 price target.